1. Search Result
Search Result
Results for "

MRSA

" in MedChemExpress (MCE) Product Catalog:

286

Inhibitors & Agonists

1

Fluorescent Dye

4

Biochemical Assay Reagents

24

Peptides

75

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-173225

    Bacterial Infection
    MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .
    MRSA/VRE-IN-1
  • HY-171233

    Bacterial Infection
    MRSA antibiotic 2 (compound 2) shows MIC of 2 μg/mL for S. aureus (MRSA). MRSA antibiotic 2 selectively target Gram-positive bacteria over Gram-negative bacteria and human cells .
    MRSA antibiotic 2
  • HY-161827

    Bacterial Infection
    Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively .
    Anti-MRSA agent 14
  • HY-144278

    Bacterial Infection Inflammation/Immunology
    Anti-MRSA agent 1 (Compound 13d) is a wonderful MRSA (MIC = 0.5 μg/mL) inhibitor. Anti-MRSA agent 1 (Compound 13d) could effectually relieve the development of MRSA resistance .
    Anti-MRSA agent 1
  • HY-163906

    Bacterial Infection
    Anti-MRSA agent 16 (Compound 4) is an inhibitor of methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 16 is effective in combination with oxacillin or meropenem in infected mice .
    Anti-MRSA agent 16
  • HY-169416

    Bacterial Reactive Oxygen Species (ROS) Infection
    Anti-MRSA agent 21 (Compound 27) has antibacterial activity against MRSA, with an MIC of 1 μM. Anti-MRSA agent 21 can damage bacterial cell membranes and increase reactive oxygen species .
    Anti-MRSA agent 21
  • HY-169160

    Bacterial Infection
    Anti-MRSA agent 18 (E17) is an inhibitor of MRSA with MIC values of 2 μg/mL for S. aureus and 4 μg/mL for MRSA, respectively. Anti-MRSA agent 18 interacts with bacterial cell membrane phosphatidylglycerol and cardiolipin, causing changes in cell membrane permeability and polarization, increased intracellular ROS, and DNA and protein leakage, thereby accelerating bacterial death .
    Anti-MRSA agent 18
  • HY-170802

    Bacterial Infection
    Anti-MRSA agent 22 (Compound 5a) is a potent antibacterial agent against MRSA with a MIC value of 6 µg/mL. Anti-MRSA agent 22 exhibits high binding affinity (−11.19) to FabI .
    Anti-MRSA agent 22
  • HY-172912

    Bacterial Infection
    Anti-MRSA agent 27 (compound 4a) is a potent anti-methicillin-resistant Staphylococcus aureus agent with a MIC of 0.0975 μmol/L. Anti-MRSA agent 27 disrupts MRSA biofilms and suppresses hemolytic toxin production .
    Anti-MRSA agent 27
  • HY-156289

    Bacterial Infection
    Anti-MRSA agent 8 (Compound 7g) is a DAPG derivative with strong antibacterial activity. Anti-MRSA agent 8 assertes its activity by targeting bacterial cell membranes. Anti-MRSA agent 8 can be used for the research of methicillin-resistant Staphylococcus aureus (MRSA) .
    Anti-MRSA agent 8
  • HY-168705

    Bacterial Infection
    Anti-MRSA agent 20 (Compound a4) is an anti-microbial agent (MIC: < 0.03125 μg/mL) against MRSA). Anti-MRSA agent 20 binds to the ribosomal peptidyl transferase center and inhibits bacterial survival by inhibiting MRSA toxin synthesis and bacterial division. Anti-MRSA agent 20 significantly reduces the MRSA load in the lungs and attenuates lung injury in the MRSA-infected mice (ED50 = 6.48 mg/kg) .
    Anti-MRSA agent 20
  • HY-146428

    Bacterial Infection
    Anti-MRSA agent 4 (compound 7a) is a potent and selective growth inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA), with MIC ≤ 0.26 µM. Anti-MRSA agent 4 exhibits no cytotoxic and no hemolytic activity in HEK293 cells .
    Anti-MRSA agent 4
  • HY-174323

    Bacterial DNA/RNA Synthesis Infection
    Anti-MRSA agent 28 is an antibacterial agent against multidrug resistant (MDR) gram-positive strains with MICs of 0.06-0.125 μg/mL. Anti-MRSA agent 28 can target DNA polymerase IIIC to reduce the amount of genomic DNA with the IC50 of 3.80 μg/mL. Anti-MRSA agent 28 has good antibacterial activity and reduces inflammation. Anti-MRSA agent 28 can be used against gram-positive strains and infectious conditions.
    Anti-MRSA agent 28
  • HY-161893

    Bacterial Infection
    Anti-MRSA agent 15 (Compound 9o10) exhibits antibacterial activity, that inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.0625 μg/mL. Anti-MRSA agent 15 exhibits low hemolysis and low cytotoxicity. Anti-MRSA agent 15 exhibits anti-infective in mice .
    Anti-MRSA agent 15
  • HY-144822

    Bacterial Infection
    Anti-MRSA agent 2 (compound 14) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and relatively low cytotoxicity in normal cells. Anti-MRSA agent 2 has strong ability to destroy bacterial membrane and bind to genomic DNA .
    Anti-MRSA agent 2
  • HY-174459

    Bacterial Penicillin-binding protein (PBP) Infection
    Anti-MRSA agent 31 (Compound 6) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent with a MIC of 97 μg/mL and a MBC of 781.25 μg/mL. Anti-MRSA agent 31 has a potent antibacterial activity and a strong Binding Protein 2a (PBP2a) inhibitory activity .
    Anti-MRSA agent 31
  • HY-144823

    Bacterial Infection
    Anti-MRSA agent 3 (compound 18) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and low cytotoxicity in normal cells. Anti-MRSA agent 3 has relatively strong ability to destroy bacterial cell wall and membrane, high binding affinity to bacterial genomic DNA .
    Anti-MRSA agent 3
  • HY-163073

    Bacterial Infection
    Anti-MRSA agent 9 (compound 39) shows antibacterial effects against clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 1 μg/ml. Anti-MRSA agent 9 also shows anti-MRSA efficacy in vivo .
    Anti-MRSA agent 9
  • HY-168873

    Bacterial Infection
    Anti-MRSA agent 23 (compound 11) is a potent anti-methicillin-resistant Staphylococcus aureus agent. Anti-MRSA agent 23 shows antibacterial and antibiofilm activities. Anti-MRSA agent 23 accelerates the reconstruction and healing of MRSA-infected cutaneous wounds by decreasing bacterial loads, attenuating inflammation, and promoting angiogenesis .
    Anti-MRSA agent 23
  • HY-161823

    Bacterial Infection
    Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies .
    Anti-MRSA agent 13
  • HY-169132

    Bacterial Infection Inflammation/Immunology
    Anti-MRSA agent 17 (8) is an inhibitor against S. aureus (MRSA) BPL (SaBPL), with a Ki of 10.3 nM .
    Anti-MRSA agent 17
  • HY-174985

    Bacterial Infection
    Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC50 value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Anti-MRSA agent 32
  • HY-147882

    Bacterial Infection
    Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent. Anti-MRSA agent 6 shows low cytoxicity for MCF-7, A549 cells .
    Anti-MRSA agent 6
  • HY-163505

    Bacterial Others
    Anti-MRSA agent 11 suppresses fluoroquinolone-sensitive strain USA500 and -resistant MRSA isolate Mu50 (MIC =0.39 μg/mL). Anti-MRSA agent 11 displayes favorable in vivo half-life and safety profiles .
    Anti-MRSA agent 11
  • HY-170847

    Bacterial Infection
    Anti-MRSA agent 24 (compound 6K) is an antimicrobial agent that targets Staphylococcus aureus (MRSA), especially penicillin-resistant Staphylococcus aureus .
    Anti-MRSA agent 24
  • HY-149013

    Bacterial Infection
    Anti-MRSA agent 5 (B14) is a potent
    MRSA
    agent with MIC50 values of 0.38 μg/mL and has low hERG activity with an IC50 values of >40 μM. Anti-MRSA agent 5 (B14) also has low cytotoxicity to mammal cells and unlikely to acquire bacterial resistance .
    Anti-MRSA agent 5
  • HY-172826

    Bacterial Infection
    Anti-MRSA agent 26 is a potent anti-MRSA agent with MIC <0.015 μg/mL. Anti-MRSA agent 26 has superior activity against a broad range of Gram-positive pathogens and shows no cytotoxicity in three mammalian cell lines (Caco-2, DU-145 and MDCKII MDR1 cells) at 10 μM. Anti-MRSA agent 26 has a robust TAP pharmacophore and an excellent antibacterial activity in Staphylococcus aureus skin infection mice model .
    Anti-MRSA agent 26
  • HY-142097

    Bacterial Infection
    Glicophenone is an antibacterial agent with MICs of both 32 μg/mL against MRSA OM481, MRSA OM505, MRSA OM584, MRSA OM623 and MSSA 209P .
    Glicophenone
  • HY-161803

    Antibiotic Bacterial Infection
    Anti-MRSA agent 12 (Compound SM-5) is an antibiotic, which exhibits antibacterial activity against Staphylococcus aureus, S. epidermidis and Escherichia coli with MIC of 7.81, 7.81 and 62.5 μM. Anti-MRSA agent 12 inhibits the methicillin-resistant S. aureus (MRSA) through inhibition of biofilm formation .
    Anti-MRSA agent 12
  • HY-173318

    Bacterial Infection
    Anti-MRSA agent 25 (Compound 10c) is an antibacterial agent with a MIC of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 25 exerts its antibacterial activity by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acids), acting on the cell membrane (causing depolarization, increasing permeability, and disrupting integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 is expected to be used in the research of the anti-infection field .
    Anti-MRSA agent 25
  • HY-161330

    Bacterial Infection
    Anti-MRSA agent 10 (Compound 2d) is a Cephalosporin (HY-144229) derivative and exhibits antibacterial activity. Anti-MRSA agent 10 is slightly drug resistane and exhibits low cytotoxicity in cells HUVEC and HBZY-1 .
    Anti-MRSA agent 10
  • HY-149271

    Bacterial DNA/RNA Synthesis Topoisomerase Infection
    Anti-MRSA agent 7 (Compound 12) is a potent antibacterial agent. Anti-MRSA agent 7 inhibits S. aureus DNA gyrase, E. coli DNA gyrase, S. aureus topo IV and E. coli topo IV with IC50s of 0.185, 0.365, 0.341 and 0.059 μM, respectively .
    Anti-MRSA agent 7
  • HY-167841

    Bacterial Antibiotic Infection
    Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against S. aureus. Anti-MRSA agent 19 is a active (median MIC=4 μg/mL) against 40 CDC isolates of different bacterial species containing various resistance factors,including Vancomycin (HY-B0671),aminoglycoside/Tetracycline (HY-A0107),and oxazolidinone resistance .
    Anti-MRSA agent 19
  • HY-N8151

    Bacterial Infection
    Sanguisorbigenin is a natural antibacterial agent that inhibits methicillin-resistant S. aureus (MRSA) .
    Sanguisorbigenin
  • HY-156009

    Others Infection
    CDFI is an inhibitor of the lipid II flippase MurJ. CDFI potentiates the activity of β-lactams against MRSA .
    CDFI
  • HY-14737
    Ceftaroline fosamil
    2 Publications Verification

    TAK-599; PPI0903

    Bacterial Antibiotic Infection
    Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .
    Ceftaroline fosamil
  • HY-P3361

    Parasite Bacterial Antibiotic Infection Inflammation/Immunology
    IDR-1018 is an innate defense regulator conjugate, with MICs of 16 μg/mL for MRSA USA300 LAC, MRSA SAP 0017 and S. epidermidis ATCC14990. IDR-1018 can be used to synthesis V-IDR1018 (vancomycin-innate defense regulator conjugate) .
    IDR-1018
  • HY-P3361A

    Parasite Bacterial Antibiotic Infection Inflammation/Immunology
    IDR-1018 acetate is an innate defense regulator conjugate, with MICs of 16 μg/mL for MRSA USA300 LAC, MRSA SAP 0017 and S. epidermidis ATCC14990. IDR-1018 acetate can be used to synthesis V-IDR1018 (vancomycin-innate defense regulator conjugate) .
    IDR-1018 acetate
  • HY-14738

    TAK-599 free acid; PPI0903 free acid

    Bacterial Antibiotic Infection
    Ceftaroline fosamil (inner) (TAK-599 free acid), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil (inner) can be used for the research of MRSA infection .
    Ceftaroline fosamil (inner)
  • HY-173478

    Topoisomerase Bacterial Antibiotic Infection
    OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
    OSUAB-0284
  • HY-P5710

    Bacterial Infection
    LCI peptide is an antimicrobial peptide with antibacterial activity. LCI peptide is active against plant pathogens, Xanthomonas and Pseudomonas, including E. coli, Gentamicin-resistant MRSA and Xoo .
    LCI peptide
  • HY-14737R

    TAK-599 (Standard); PPI0903 (Standard)

    Reference Standards Bacterial Antibiotic Infection
    Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].
    Ceftaroline fosamil (Standard)
  • HY-172813

    Bacterial Antibiotic Autophagy Infection Cancer
    Vancomycin prodrug (compound 13c) is a Vancomycin (HY-B0671) prodrug. Vancomycin prodrug shows antibacterial effect with MICs of 0.78 μM, 0.78 μM, 1.56 μM for S. aureus 330041, MRSA USA 300 and MRSA 3390, respectively. Vancomycin prodrug has the ability to quickly bind to Cys-34 residue of plasma. Vancomycin prodrug exhibits a good therapeutic effect on MRSA USA300 infected mice similar to Vancomycin. Vancomycin prodrug, an albumin-binding acid-sensitive prodrug, effectively reduces Vancomycin’s nephrotoxicity while maintaining its efficacy for Gram-positive bacterial infections .
    Vancomycin prodrug
  • HY-P10345

    Bacterial Infection
    OP-145, an cathelicidin LL-37 derivative, is an antimicrobial peptide, and shows antibacterial activity against several MRSA strains. OP-145 can be used for research of chronic suppurative otitis media .
    OP-145
  • HY-14784

    REP8839

    Bacterial Infection
    Bederocin (REP8839) is a Methionyl-tRNA synthetase inhibitor. Bederocin can be used in research of bacterial infection, including S. aureus and MRSA .
    Bederocin
  • HY-146199

    Bacterial Infection
    Antibacterial agent 108 (Compound 1h) is a potent antibacterial agent with a MIC of both 3 μM against MRSA and antibiotic resistance strains .
    Antibacterial agent 108
  • HY-P5709

    Bacterial Infection Inflammation/Immunology
    HG4 is a fast-acting antimicrobial peptide. HG4 shows anti-biofilm and anti-inflammatory activities. HG4 is active against Gram-positive pathogens, especially against MRSA strains (MIC: 32-64?μg/mL). HG4 can bind to bacterial lipids and reduces ATP concentration in S. aureus MRSA USA300 cells .
    HG4
  • HY-P5706

    Bacterial Infection Inflammation/Immunology
    HG2 is a fast-acting antimicrobial peptide. HG2 shows anti-biofilm and anti-inflammatory activities. HG2 is active against Gram-positive pathogens, especially against MRSA strains (MIC: 16-32?μg/mL). HG2 can bind to bacterial lipids and reduces ATP concentration in S. aureus MRSA USA300 cells .
    HG2
  • HY-125747
    Actinomycin X2
    1 Publications Verification

    Actinomycin V

    Bacterial Antibiotic Apoptosis Infection Cancer
    Actinomycin X2 (Actinomycin V),produced by many Streptomyces sp.,shows strong inhibition of MRSA with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection .
    Actinomycin X2
  • HY-147755

    Bacterial Infection
    C16-K-cBB1 is a potent and selective antimicrobial agent for MRSA (Methicillin resistant Staphylococcus aureus), with a MIC of 1 µg/mL. C16-K-cBB1 has very good selectivity, as it has weak hemolytic activity. C16-K-cBB1 is able to kill MRSA cells in a matter of 120 min at a concentration of 12.5 μg/mL .
    C16-K-cBB1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: